In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GW/Bayer: Sharing Value

Executive Summary

In its late-stage licensing deal with GW Pharmaceuticals for Sativex, Bayer accepted UK-only rights, and will share the product's value equally with GW. This unusual agreement largely reflects the particular nature of the product. But it also shows that, at least in some situations, biotechs can still partner out their jewels without giving away too much value.

You may also be interested in...

The Pan European Licensing Opportunity

Since 2000, there have been almost four times more product licensing deals signed for North America than for Europe. Granted, Europe is a more complex market, and the US produces a higher proportion of new drugs. But the figures spell a big opportunity for those firms able to offer truly pan-European scope and expertise.

Bayer Leans on Vardenafil

Dubbed "the new blockbuster" by Bayer AG management, the PDE5 inhibitor vardenafil is by most accounts more potent, faster acting, and less prone to side effects than its pharmaceutical cousin, Pfizer Inc.'s sildenafil (Viagra). But vardenafil's potential-and its role as a potential savior of Bayer's ailing pharmaceuticals division-may be overshadowed by the chinks that this same promise has helped expose in the Bayer armor.

GW Pharmaceuticals PLC

GW is developing cannabis-based pharmaceuticals using extracts taken from plants which are specially bred to optimize the therapeutic benefit of cannabis.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts